NCCN clinical practice guidelines in oncology: prostate cancer early detection.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 20141680
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance

  2009cited by this paper
• Mortality results from a randomized prostate-cancer screening trial.

  2009cited by this paper
• Current prostate biopsy interpretation: criteria for cancer, atypical small acinar proliferation, high-grade prostatic intraepithelial neoplasia, and use of immunostains.

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Screening and prostate-cancer mortality in a randomized European study.

  2009cited by this paper
• Serum PSA and Percent Free PSA Value Changes after Antibiotic Treatment

  2008cited by this paper
• Prostate specific antigen testing among the elderly--when to stop?

  2008cited by this paper
• Prostate-specific antigen velocity risk count assessment: a new concept for detection of life-threatening prostate cancer during window of curability.

  2007cited by this paper
• Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

  2007cited by this paper
• Baseline prostate-specific antigen compared with median prostate-specific antigen for age group as predictor of prostate cancer risk in men younger than 60 years old.

  2006cited by this paper
• Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.

  2006cited by this paper
• The detection and potential economic value of complexed prostate specific antigen as a first line test.

  2006cited by this paper
• Risk of prostate cancer on first re-biopsy within 1 year following a diagnosis of high grade prostatic intraepithelial neoplasia is related to the number of cores sampled.

  2006cited by this paper
• Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.

  2006cited by this paper
• Usefulness of the (F/T)/PSA Density Ratio to Detect Prostate Cancer

  2005cited by this paper
• Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.

  2005cited by this paper
• Usefulness of basal cell cocktail (34betaE12 + p63) in the diagnosis of atypical prostate glandular proliferations.

  2004cited by this paper
• Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

  2004cited by this paper
• Herbal and vitamin supplement use in a prostate cancer screening population.

  2004cited by this paper
• Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.

  2004cited by this paper
• Characteristics of prostate cancers detected at low PSA levels

  2004cited by this paper
• Impact of prior biopsy scheme on pathologic features of cancers detected on repeat biopsies.

  2004cited by this paper
• Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy.

  2004cited by this paper
• Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.

  2003cited by this paper
• PSA density and PSA transition zone density in the diagnosis of prostate cancer in PSA gray zone cases.

  2003cited by this paper
• Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study.

  2003cited by this paper
• Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density.

  2003cited by this paper
• The utility of apical anterior horn biopsies in prostate cancer detection.

  2003cited by this paper
• Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen.

  2003cited by this paper
• Predictors of cancer in repeat extended multisite prostate biopsy in men with previous negative extended multisite biopsy.

  2002cited by this paper
• Hereditary prostate cancer: clinical aspects.

  2002cited by this paper
• Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study.

  2002cited by this paper
• Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force

  2002cited by this paper
• Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.

  2002cited by this paper
• Comparison of local anesthesia techniques during transrectal ultrasound-guided biopsies.

  2002cited by this paper
• Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing.

  2002cited by this paper
• Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer.

  2002cited by this paper
• Followup interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels.

  2002cited by this paper
• Local anesthesia for prostate biopsy by periprostatic lidocaine injection: a double-blind placebo controlled study.

  2002cited by this paper
• Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter.

  2002cited by this paper
• Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging.

  2001cited by this paper
• Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng./ml.

  2001cited by this paper
• Prostate cancer diagnosis using a saturation needle biopsy technique after previous negative sextant biopsies.

  2001cited by this paper
• The incidence of prostate cancer in a screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy.

  2001cited by this paper
• Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

  2000cited by this paper
• The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial.

  2000cited by this paper
• A comparative analysis of sextant and an extended 11-core multisite directed biopsy strategy.

  2000cited by this paper
• Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359

  1999cited by this paper
• Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

  1998cited by this paper
• Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements.

  1997cited by this paper
• Age-specific reference ranges for serum prostate-specific antigen in black men.

  1996cited by this paper
• Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.

  1995cited by this paper
• A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.

  1995cited by this paper
• Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

  1994cited by this paper
• Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges.

  1993cited by this paper
• Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination.

  1993cited by this paper
• Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening.

  1993cited by this paper
• Multiple transrectal ultrasound-guided prostatic biopsies--true morbidity and patient acceptance.

  1993cited by this paper
• Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease.

  1992cited by this paper
• Mendelian inheritance of familial prostate cancer.

  1992cited by this paper
• Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer.

  1992cited by this paper

• Assessing genetic and urologic providers on renal screening recommendations for individuals with a familial renal cancer risk

  2025cites this paper
• Single-layer biosensor for urinary prostate-cancer biomarkers through transition-metal-doped graphene: a DFT study

  2025cites this paper
• Geographic Variability in Germline Genetic Testing for Prostate Cancer: A Nationwide Medicare Claims Study With Evidence of Low Uptake.

  2025cites this paper
• PROSTest, a Novel Liquid Biopsy Molecular Assay, Accurately Guides Prostate Cancer Biopsy Decision-Making in Men with Elevated PSA Irrespective of DRE Findings

  2025cites this paper
• A Clinical Nomogram to Predict Survival Outcomes in Patients with Well-Differentiated Thyroid Cancer

  2025cites this paper
• Prostate biopsy in patients without rectal access: a systematic review and proportional meta-analysis

  2025cites this paper
• Shared decision-making before prostate cancer screening decisions

  2024cites this paper
• Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Radiomic Models in Prostate Cancer Prognostication

  2024cites this paper
• Heterotopic Splenic Tissue Mimicking Metastases on Magnetic Resonance Imaging

  2024cites this paper
• Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of Prostate Cancer

  2024cites this paper
• The Use of MRI-Derived Radiomic Models in Prostate Cancer Risk Stratification: A Critical Review of Contemporary Literature

  2023cites this paper
• Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors.

  2023cites this paper
• Development and Validation of Nomograms Predicting the 5- and 8-Year Overall and Cancer-Specific Survival of Bladder Cancer Patients Based on SEER Program

  2023cites this paper
• Impact of an NCCN-Compliant Multidisciplinary Conference on Treatment Decisions for Localized Prostate Cancer.

  2023cites this paper
• A nomogram for predicting overall survival of patients with squamous cell carcinoma of the floor of the mouth: a population-based study

  2023cites this paper
• Awaiting the perfect diagnostic test: optimal prostate cancer care begins without a diagnosis

  2022cites this paper
• Protocol Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer

  2022cites this paper
• Assessment of age as different variable types for determining survival in differentiated thyroid cancer

  2022cites this paper
• Accuracy of prostate cancer screening recommendations for high‐risk populations on YouTube and TikTok

  2022cites this paper
• Urothelial carcinoembryonic antigen 1 score for early detection of prostate cancer and risk prediction

  2022cites this paper
• Number of prostate-specific antigen (PSA) screening tests in the last five years reported by men in the United States in 2010, 2015, and 2018.

  2022cites this paper
• CanRisk-Prostate: A Comprehensive, Externally Validated Risk Model for the Prediction of Future Prostate Cancer

  2022cites this paper
• 5-Alpha Reductase Inhibitor Use and Prostate Cancer Prevention: A Victim of the Times?

  2022cites this paper
• Recent Advances in Prostate Cancer (PCa) Diagnostics

  2022cites this paper
• Racial disparities in Black men with prostate cancer: A literature review

  2022cites this paper
• Metabolic Phenotyping in Prostate Cancer Using Multi-Omics Approaches

  2022cites this paper
• An appraisal of genetic testing for prostate cancer susceptibility

  2022cites this paper
• SEOM clinical guidelines for the prophylaxis of infectious diseases in cancer patients (2021)

  2022cites this paper
• Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy

  2021cites this paper
• Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer

  2021cites this paper
• Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes

  2021cites this paper
• Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk

  2021cites this paper
• Inherited Mutations in Chinese Men With Prostate Cancer.

  2021cites this paper
• Value of transrectal contrast-enhanced ultrasound with clinical indicators in the prediction of bone metastasis in prostate cancer.

  2021cites this paper
• Clinical utility of current biomarkers for prostate cancer detection.

  2020cites this paper
• Reproductive Care of Childhood and Adolescent Cancer Survivors: A 12-Year Evaluation

  2020cites this paper
• Construction and validation of a nomogram for predicting cancer-specific survival in hepatocellular carcinoma patients

  2020cites this paper
• Applying nomograms based on the surveillance, epidemiology and end results database to predict long-term overall survival and cancer-specific survival in patients with oropharyngeal squamous cell carcinomas

  2020cites this paper
• Hereditary Predisposition to Prostate Cancer: From Genetics to Clinical Implications

  2020cites this paper
• Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019.

  2020cites this paper
• Cancer Surveillance in Healthy Carriers of Germline Pathogenic Variants in BRCA1/2: A Review of Secondary Prevention Guidelines

  2020cites this paper
• A New Nomogram Allowing Physicians to Predict Patients at High Risk of Fever Occurring After Prostate Biopsy

  2020cites this paper
• Nomogram for Predicting Survival in Mucinous Adenocarcinoma of Prostate

  2020cites this paper
• Development and validation of an explainable artificial intelligence‐based decision‐supporting tool for prostate biopsy

  2020cites this paper
• Prostate Biopsy up Date

  2020cites this paper
• Might definitive local therapy of the primary tumor improve the survival benefits of metastatic prostate cancer? -evidence from a meta-analysis.

  2020cites this paper
• Early detection of prostate cancer using prostate-specific antigen testing: an empirical evaluation among general practitioners and urologists

  2019cites this paper
• CMAR_A_194366 3535..3544

  2019cites this paper
• A review of optimal prostate biopsy: indications and techniques

  2019cites this paper
• Atypical Glands Suspicious for Cancer (ATYP)

  2019cites this paper
• Nomograms for predicting long-term overall survival and cancer-specific survival in patients with primary urethral carcinoma: a population-based study

  2019cites this paper
• Establishing a prediction model for prostate cancer bone metastasis

  2019cites this paper
• Nomogram predicting long-term overall survival and cancer-specific survival of lip carcinoma patients based on the SEER database

  2019cites this paper
• How to choose proper local treatment in men aged ≥75 years with cT2 localized prostate cancer?

  2019cites this paper
• Nomograms for estimating survival in patients with papillary thyroid cancer after surgery

  2019cites this paper
• Nomograms for predicting long‐term overall survival and cancer‐specific survival in lip squamous cell carcinoma: A population‐based study

  2019cites this paper
• Analysis of the prognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with definitive therapy

  2019cites this paper
• Effect of Level of Urology Training on Gleason Score and Prostate Volume Estimation Agreement between Transrectal Ultrasound Guided Biopsy and Radical Prostatectomy Specimen

  2018cites this paper
• Shared decision-making for prostate cancer screening and treatment: a systematic review of randomised controlled trials.

  2018cites this paper
• Saturation Biopsy for Diagnosis, Staging and Management of Prostate Cancer

  2018cites this paper
• A Devastatingly “Minor” Relationship Between Male Breast Cancer and Prostate Cancer

  2018influential citation
• Nomograms forecasting long‐term overall and cancer‐specific survival of patients with oral squamous cell carcinoma

  2018cites this paper
• Survival outcomes in elderly men undergoing radical prostatectomy in Australia

  2018cites this paper
• PSA Screening for Prostate Cancer in Men under the Age of 65: A Review of Current Practice

  2018influential citation
• Prognostic nomogram for disease‐specific survival of carcinoma ex pleomorphic adenoma of the salivary gland

  2017cites this paper
• Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer

  2017cites this paper
• Saturation Biopsy for Diagnosis, Staging, and Management of Prostate Cancer

  2017cites this paper
• The role of prostate cancer biomarkers in undiagnosed men

  2017cites this paper
• Is Prostate Biopsy Recommended in Turkish Men with a Prostate-Specific Antigen Level between 2.5 and 4 ng/mL?

  2017cites this paper
• Advice About Screening for Prostate Cancer With Prostate-Specific Antigen

  2017cites this paper
• Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study

  2017cites this paper
• The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study

  2017cites this paper
• Nomograms for predicting long-term overall survival and cancer-specific survival in patients with major salivary gland cancer: a population-based study

  2017cites this paper
• Predicting prostate cancer treatment choices: The role of numeracy, time discounting, and risk attitudes

  2017cites this paper
• Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer

  2017cites this paper
• Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.

  2016cites this paper
• Title Prospective Pilot Trial to Evaluate a High Resolution Diffusion-Weighted MRI in Prostate Cancer Patients Permalink

  2016cites this paper
• MP50-08 CAN ANGIOTENSIN-CONVERTING ENZYME INHIBITORS REDUCE THE INCIDENCE, SEVERITY, AND DURATION OF RADIATION PROCTITIS?

  2016cites this paper
• Lessons Learned from Implementing a Prostate Cancer Risk Assessment Program for Underserved High-Risk Men in the Community: the Prostate REACH Project

  2016cites this paper
• Prospective Pilot Trial to Evaluate a High Resolution Diffusion-Weighted MRI in Prostate Cancer Patients

  2016cites this paper
• Nomograms predicting long-term overall survival and cancer-specific survival in head and neck squamous cell carcinoma patients

  2016cites this paper
• Contemporary National Trends of Prostate Cancer Screening Among Privately Insured Men in the United States.

  2016cites this paper
• The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening.

  2016cites this paper
• Evaluation of the Prostate Imaging Reporting and Data System for Magnetic Resonance Imaging Diagnosis of Prostate Cancer in Patients with Prostate-specific Antigen <20 ng/ml

  2016influential citation
• Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines Part 1

  2016cites this paper
• More Favorable Pathological Outcomes in Men with Low Risk Prostate Cancer Diagnosed on Repeat versus Initial Transrectal Ultrasound Guided Prostate Biopsy.

  2016cites this paper
• Rentabilidad de la biopsia prostática y determinación de valores del psa: incidencia de cáncer prostático y complicaciones postbiopsia

  2016cites this paper
• The Prostate Health Index: Its Utility in Prostate Cancer Detection.

  2016cites this paper
• Real-time source tracking for quality assurance in HDR prostate brachytherapy

  2015cites this paper
• DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis

  2015cites this paper
• Prädiktoren eines positiven Schnittrandes und dessen Auswirkung auf die onkologischen Langzeitergebnisse nach transperitonealer radikaler laparoskopischer Prostatektomie retrospektive Studie bei über 1.800 Patienten in den Jahren 1999 - 2007 an der Klinik für Urologie der Charité

  2015cites this paper
• Use of statins and serum levels of Prostate Specific Antigen

  2015cites this paper
• Nomograms for predicting survival and recurrence in patients with adenoid cystic carcinoma. An international collaborative study.

  2015cites this paper
• Video‐based educational tool improves patient comprehension of common prostate health terminology

  2015cites this paper
• When prostate cancer remains undetectable: The dilemma.

  2015cites this paper
• Combination of Autoantibody Signature with PSA Level Enables a Highly Accurate Blood-Based Differentiation of Prostate Cancer Patients from Patients with Benign Prostatic Hyperplasia

  2015cites this paper
• Postoperative Nomogram for Predicting Cancer-Specific Mortality in Medullary Thyroid Cancer

  2015cites this paper
• Prostate-specific antigen velocity is not better than total prostate-specific antigen in predicting prostate biopsy diagnosis.

  2015cites this paper
• National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.

  2015cites this paper
• Impact of the US Preventive Services Task Force Grade D Recommendation: Assessment of Evaluations for Elevated Prostate-specific Antigen and Prostate Biopsies in a Large Urology Group Practice Following Statement Revision.

  2015cites this paper